Retatrutide

What is Retatrutide?

Retatrutide is an experimental peptide therapy developed as a “triple agonist,” meaning it simultaneously activates GLP-1, GIP, and glucagon receptors. This unique mechanism positions it as one of the most promising compounds in obesity and metabolic disorder research. By combining three pathways involved in appetite, energy balance, and glucose control, Retatrutide is being studied as a next-generation alternative to single-pathway GLP-1 drugs like Ozempic (semaglutide).

How Does Retatrutide Work?

Retatrutide binds to three hormone receptors:

• GLP-1 Receptors: Regulate insulin secretion, blood sugar, and satiety.
• GIP Receptors: Enhance insulin response and may improve fat metabolism.
• Glucagon Receptors: Increase energy expenditure and support fat oxidation.

This triple action is designed to suppress appetite, increase caloric burn, and improve insulin sensitivity more effectively than GLP-1 agonists alone.

Chemical Properties

Potential Benefits of Retatrutide (Research Settings)

• Weight Loss: Early studies show dramatic reductions in body weight, exceeding results from semaglutide.
• Metabolic Improvements: Enhances insulin sensitivity and supports glucose regulation.
• Increased Energy Expenditure: Glucagon receptor activity promotes fat oxidation and higher metabolic output.
• Cardiovascular Health: Research suggests potential improvements in blood pressure, lipids, and inflammation markers.

Clinical Research & Findings

Retatrutide has been evaluated in early human trials, including studies published in The New England Journal of Medicine. Results indicate unprecedented weight loss—up to 24% of body weight in certain research groups. These findings suggest it may surpass current GLP-1 receptor agonists in effectiveness for obesity and metabolic health, though research is ongoing and regulatory approval has not yet been granted.

Dosage & Research Protocols

• Research Dose: 1–12 mg weekly (subcutaneous)
• Administration: Subcutaneous injection, once per week
• Cycle Length: 12–24 weeks or longer depending on study design

Doses are typically escalated over time in research models to improve tolerance and maximize outcomes, similar to semaglutide and tirzepatide protocols.

FAQs

Is Retatrutide legal in Canada?

Yes. Retatrutide is available for research use in Canada but is not yet approved for clinical or consumer use.

How is Retatrutide different from Ozempic?

Ozempic is a GLP-1 receptor agonist, while Retatrutide is a triple agonist that also targets GIP and glucagon receptors for stronger weight and metabolic effects.

What are the main research applications of Retatrutide?

Studies focus on obesity, insulin resistance, type 2 diabetes, and cardiometabolic health markers.

What form does Retatrutide come in?

It is supplied in lyophilized powder or injectable solution form with ≥98% purity for laboratory research purposes.

Disclaimer

For laboratory use only. Not for human or veterinary use.

This compound is intended strictly for research under controlled laboratory conditions. Researchers and institutions must ensure legal and ethical compliance with local and federal regulations.